Daré Bioscience ( (DARE) ) has released its Q3 earnings. Here is a breakdown of the information Daré Bioscience presented to its investors.
Daré Bioscience is a biopharmaceutical company focused on women’s health, developing a range of innovative therapies for conditions such as contraception, sexual health, and menopause.
In its third-quarter 2024 earnings report, Daré Bioscience highlighted its ongoing development projects and financial performance, including a significant foundation grant to support its contraceptive research.
Key financial metrics from the report include a 60% decrease in research and development expenses compared to the previous year, primarily due to the completion of a Phase 2b study for Sildenafil Cream. The company also reported a net loss of $4.7 million for the quarter, a notable improvement from the $8.3 million loss in the same quarter of 2023. An important strategic announcement was the expansion of the Phase 3 study of Ovaprene, supported by a $10.7 million grant to accelerate the timeline.
Furthermore, Daré Bioscience is advancing its Sildenafil Cream, aimed at treating female sexual arousal disorder, with plans for Phase 3 studies. The company secured additional funding through strategic partnerships and grants, positioning it for significant milestones in 2025.
Looking forward, Daré Bioscience remains committed to developing first-in-category treatments for women’s health, leveraging recent grants and strategic collaborations to drive progress across its portfolio. Management expressed optimism about achieving meaningful milestones in the coming year.
